FINWIRES · TerminalLIVE
FINWIRES

Australian Shares Continues to Decline; Santos Reports Lower Q1 Revenue, Higher Production

-- Australian shares again fell at Thursday's close as oil prices gained on the continued closure of the critical Strait of Hormuz in the Middle East.

The S&P/ASX 200 Index declined 0.57%, or by 50.20 points, to close at 8,793.40.

Brent crude oil futures gained 1.4% on Thursday to reach $103.3 per barrel. Iran captured two container ships ​seeking to exit the Gulf via the Strait of Hormuz.

On Wall Street, the S&P 500 rose 1.1%, and the Nasdaq climbed 1.6% to reach new record ​high points as the earnings season started. The Dow Jones rose 0.7%.

On the domestic front, The Flash Australia PMI Composite Output Index rose to 50.1 in April from 46.6 in March, moving above the neutral threshold as renewed growth in services activity offset a faster decline in manufacturing output, according to a survey by S&P Global.

Australia's private sector activity stabilized in April after March's decline, as a modest recovery in services was offset by continued weakness in manufacturing amid soft domestic demand, rising cost pressures, and supply chain disruptions linked to Middle East tensions.

Job advertisements in Australia in March fell 0.4% month on month, 1.3% quarter on quarter, and 2.9% year on year, according to data published by Seek.

In company news, Santos (ASX:STO) reported first-quarter sales revenue of about $1.27 billion, down from $1.29 billion in the year-ago period. Sales volume for the quarter was 24.2 million barrels of oil equivalent (mmboe), up from 23.3 mmboe a year earlier, while total production increased to 22.5 mmboe in the first quarter from 21.9 mmboe a year ago. Its shares rose 3% on market close.

Ampol (ASX:ALD) submitted its final remedy package to the Australian Competition and Consumer Commission (ACCC) on Wednesday for its proposed acquisition of EG Australia, offering to increase the number of planned divestments to 41 sites from 37. Its shares closed up over 1%.

Lastly, Mirvac Group (ASX:MGR) said residential sales for the fiscal third quarter reached 592 sales, up 12% year on year. The company said year-to-date settlements reached 1,076, up 15% year on year, with about 96% of the fiscal 2026 target lot settlements secured and margins on track to be within the 18% to 22% target range. Its shares were down over 1% on market close.

Related Articles

Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Ibm Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target by $37 to $296, 23x our 2026 EPS view, above IBM's three-year average (~20x) on AI tailwinds and growing software exposure. We raise our 2026 EPS view by $0.07 to $12.86 and lift 2027's by $0.03 to $13.90. Q1 results offered a mixed response to the AI competition threat. Bears will focus on Software growth (ex-FX) decelerating to 8% from 11% in Q4 with the segment's 2026 outlook improving only slightly to 10%+ from 10% despite the Confluent acquisition closing early (providing a ~50-bp Software growth boost). Some analysts expected more out of Consulting and will point to its modest 1% sales growth as indicative of COBOL modernization pressure from emerging AI tools. We take a more bullish stance and see Consulting results as resilient, with sales/signings both growing despite ongoing macroeconomic pressures and 2026 growth still forecasted near 5%. On the Software side, ARR again grew 10% Y/Y (consistent with prior periods) and Red Hat encouragingly rebounded to 10% from 8% in Q4.

$IBM
Australia

Regeneron Says FDA Granted Accelerated Approval for Genetic Hearing Loss Therapy

Regeneron (REGN) said Thursday that the US Food and Drug Administration has granted accelerated approval for Otarmeni therapy indicated for the treatment of pediatric and adult patients with OTOF gene-related hearing loss.FDA's approval was based on the ongoing Chord trial that showed 16 of 20 participants experienced hearing improvements per pure tone audiometry assessments, while 14 out of 20 demonstrated an auditory brainstem response, according to a statement.Otarmeni's continued approval may be contingent upon verification and description of clinical benefit in the confirmatory portion of the Chord trial, Regeneron said.The company said it will provide Otarmeni at no cost to clinically eligible individuals in the US.Shares of the company were up 2% in Thursday trading.Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN
Sectors

Sector Update: Health Care

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.9%.In corporate news, Thermo Fisher Scientific (TMO) raised its full-year outlook on Thursday as Q1 results came in stronger than expected, even as organic growth fell short of analysts' estimates. Its shares fell 10.9%.

$TMO